Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Hoekstra

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
FEBS Letters|January 2, 1996
RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen gamma-chain C-terminal peptideK H Mayo, F Fan, M P Beavers, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|July 5, 2001
Tritiated photoactivatable analogs of the native human thrombin receptor (PAR-1) agonist peptide, SFLLRN-NH2J T Elliott, W J Hoekstra, C K Derian, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study GroupP F Mulders, W J Hoekstra, R P Heybroek, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2001
1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonistsE C Lawson, W J Hoekstra, M F Addo, et al.
Archives of Biochemistry and Biophysics|May 23, 2001
Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopesB E Maryanoff, R J Santulli, D F McComsey, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motifW J Hoekstra, B L Hulshizer, D F McComsey, et al.
Thrombosis Research|October 24, 2001
Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonistB P Damiano, J A Mitchell, E Giardino, et al.
Journal of Medicinal Chemistry|May 12, 1995
Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonistsW J Hoekstra, M P Beavers, P Andrade-Gordon, et al.
Antimicrobial Agents and Chemotherapy|September 17, 2014
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzymeA G S Warrilow, C M Hull, J E Parker, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptorP Andrade-Gordon, B E Maryanoff, C K Derian, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
FEBS Letters|January 2, 1996
RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen gamma-chain C-terminal peptideK H Mayo, F Fan, M P Beavers, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|July 5, 2001
Tritiated photoactivatable analogs of the native human thrombin receptor (PAR-1) agonist peptide, SFLLRN-NH2J T Elliott, W J Hoekstra, C K Derian, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study GroupP F Mulders, W J Hoekstra, R P Heybroek, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2001
1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonistsE C Lawson, W J Hoekstra, M F Addo, et al.
Archives of Biochemistry and Biophysics|May 23, 2001
Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopesB E Maryanoff, R J Santulli, D F McComsey, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motifW J Hoekstra, B L Hulshizer, D F McComsey, et al.
Thrombosis Research|October 24, 2001
Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonistB P Damiano, J A Mitchell, E Giardino, et al.
Journal of Medicinal Chemistry|May 12, 1995
Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonistsW J Hoekstra, M P Beavers, P Andrade-Gordon, et al.
Antimicrobial Agents and Chemotherapy|September 17, 2014
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzymeA G S Warrilow, C M Hull, J E Parker, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptorP Andrade-Gordon, B E Maryanoff, C K Derian, et al.
Pageof 3